ES2152941T3 - Utilizacion de lipasa activada de sal biliar como suplemento dietetico. - Google Patents

Utilizacion de lipasa activada de sal biliar como suplemento dietetico.

Info

Publication number
ES2152941T3
ES2152941T3 ES93203480T ES93203480T ES2152941T3 ES 2152941 T3 ES2152941 T3 ES 2152941T3 ES 93203480 T ES93203480 T ES 93203480T ES 93203480 T ES93203480 T ES 93203480T ES 2152941 T3 ES2152941 T3 ES 2152941T3
Authority
ES
Spain
Prior art keywords
dietary supplement
lipase
salt
activated
activated lipase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93203480T
Other languages
English (en)
Inventor
Jordan J N Tang
Chi-Sun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Application granted granted Critical
Publication of ES2152941T3 publication Critical patent/ES2152941T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
    • A23C9/1216—Other enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S426/00—Food or edible material: processes, compositions, and products
    • Y10S426/801—Pediatric

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dairy Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PREVE UN METODO PARA TRATAR SUJETOS QUE PADECEN UNA PRODUCCION INADECUADA DE ENZIMA PANCREATICA POR ADMINISTRACION DE LIPASA DE SAL BILIAR ACTIVADA EN CONJUNCION CON LA INGESTION DE GRASAS. LA LIPASA DE SAL BILIAR ACTIVADA SE PROPORCIONA EN UNA DOSIS QUE PREVE AL MENOS 1 MG DE LIPASA/2000 MG DE GRASA INGERIDA.
ES93203480T 1987-11-19 1988-11-18 Utilizacion de lipasa activada de sal biliar como suplemento dietetico. Expired - Lifetime ES2152941T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/122,410 US4944944A (en) 1987-11-19 1987-11-19 Dietary compositions and methods using bile salt-activated lipase

Publications (1)

Publication Number Publication Date
ES2152941T3 true ES2152941T3 (es) 2001-02-16

Family

ID=22402581

Family Applications (2)

Application Number Title Priority Date Filing Date
ES88310942T Expired - Lifetime ES2120402T3 (es) 1987-11-19 1988-11-18 Composiciones dieteticas y procedimientos de utilizacion de lipasa activada por sal biliar.
ES93203480T Expired - Lifetime ES2152941T3 (es) 1987-11-19 1988-11-18 Utilizacion de lipasa activada de sal biliar como suplemento dietetico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES88310942T Expired - Lifetime ES2120402T3 (es) 1987-11-19 1988-11-18 Composiciones dieteticas y procedimientos de utilizacion de lipasa activada por sal biliar.

Country Status (7)

Country Link
US (1) US4944944A (es)
EP (2) EP0317355B1 (es)
JP (2) JP2592939B2 (es)
AT (2) ATE167982T1 (es)
DE (2) DE3856214T2 (es)
ES (2) ES2120402T3 (es)
GR (1) GR3035093T3 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4944944A (en) * 1987-11-19 1990-07-31 Oklahoma Medical Research Foundation Dietary compositions and methods using bile salt-activated lipase
US5200183A (en) * 1987-11-19 1993-04-06 Oklahoma Medical Research Foundation Recombinant bile salt activated lipases
US5000975A (en) * 1988-12-29 1991-03-19 American Home Products Corporation Randomized palm oil fat composition for infant formulas
US5008120A (en) * 1989-07-21 1991-04-16 Snow Brand Milk Products Co., Ltd. Method of preparing iron-fortified beverage
US5173408A (en) * 1989-11-13 1992-12-22 Lange Louis George Iii Mammalian pancreatic cholesterol esterase
JP2808166B2 (ja) * 1990-04-26 1998-10-08 雪印乳業株式会社 鉄強化飲料の製造方法
US5186961A (en) * 1991-03-15 1993-02-16 North Carolina State University Method and composition for maintaining animals on a keratin-containing diet
US5169666A (en) * 1991-11-14 1992-12-08 The United States Of America As Represented By The Secretary Of Agriculture Preparation of simulated human milk protein by low temperature microfiltration
US5902617A (en) * 1992-05-19 1999-05-11 Pabst; Patrea L. Enzyme supplemented baby formula
HRP930935A2 (en) * 1992-06-11 1994-12-31 Astra Ab New dna sequences
GB9212511D0 (en) * 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
US5460812A (en) * 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
IS4130A (is) * 1993-03-01 1994-09-02 Ab Astra Ný fjölpeptíð
US5821226A (en) * 1994-12-01 1998-10-13 Oklahoma Medical Research Foundation BAL C-tail drug delivery molecules
US5681819A (en) * 1994-12-01 1997-10-28 Oklahoma Medical Research Foundation Method and compositions for reducing cholesterol absorption
US5696087A (en) * 1994-12-01 1997-12-09 Oklahoma Medical Research Foundation Method and compositions for reducing cholesterol absorption
US6342218B1 (en) 1997-02-14 2002-01-29 Oklahoma Medical Research Foundation Method for treatment of SLE
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US7008776B1 (en) * 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US6395530B1 (en) * 1996-12-06 2002-05-28 Aventis Pharmaceuticals Inc. LLG polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies
ES2331442T3 (es) 1998-03-23 2010-01-04 General Mills, Inc. Encapsulacion de componentes en productos comestibles.
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
ATE413889T1 (de) * 1998-06-05 2008-11-15 Nutrinia Ltd Insulin angereichertes säuglingsnährpräparat
US6399090B1 (en) * 1998-06-05 2002-06-04 Insotech Ltd. Insulin supplemented infant formula
WO2001089553A1 (en) * 1999-05-19 2001-11-29 Barnes Jewish Hospital Enhanced triglyceride digestion in a deficiency of bile salts
EP1059041A1 (en) * 1999-06-07 2000-12-13 Universiteit Gent The combined use of triglycerides containing medium chain fatty acids and exogenous lipolytic enzymes as feed supplements
US6500463B1 (en) 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
US6468568B1 (en) 2000-06-16 2002-10-22 General Mills, Inc. Oligosaccharide encapsulated mineral and vitamin ingredients
US6436453B1 (en) 2000-06-16 2002-08-20 General Mills, Inc. Production of oil encapsulated minerals and vitamins in a glassy matrix
US6558718B1 (en) 2000-06-19 2003-05-06 General Mills, Inc. Nutrient clusters for food products and methods of preparation
EP1539222A1 (en) * 2002-07-02 2005-06-15 The Regents Of The University Of California Treatment for eye disorder
US7431986B2 (en) 2002-07-24 2008-10-07 General Mills, Inc. Encapsulation of sensitive components using pre-emulsification
CA3007908A1 (en) 2003-03-07 2005-04-14 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US7803413B2 (en) 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
WO2007053619A2 (en) * 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
EP1987142A4 (en) 2006-02-02 2009-07-15 Verenium Corp ESTERASES AND ASSOCIATED NUCLEIC ACIDS AND METHODS
AR059692A1 (es) * 2007-03-01 2008-04-23 Adriana Fernandez Alimento de alto contenido calorico y de facil digestion
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
EP2629789A1 (en) * 2010-10-21 2013-08-28 Swedish Orphan Biovitrum AB (Publ) Method to increase the absorption of unsaturated fatty acids by human infants
WO2012052060A1 (en) 2010-10-21 2012-04-26 Swedish Orphan Biovitrum Ab (Publ) Method to increase the growth velocity of human infants
AU2013221572B2 (en) 2012-02-17 2017-12-21 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
GB201501081D0 (en) 2015-01-22 2015-03-11 Cilian Ag Use of enzymes with a wide pH activity range as medicaments for promoting digestion
US10258590B2 (en) 2015-10-14 2019-04-16 Alcresta Therapeutics, Inc. Enteral feeding device and related methods of use
ES2957891T3 (es) 2016-03-24 2024-01-29 Elgan Pharma Ltd Uso de insulina para promover el vaciamiento gástrico
US11045396B2 (en) 2017-08-17 2021-06-29 Alcresta Therapeutics, Inc. Devices and methods for the supplementation of a nutritional formula

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA662815A (en) * 1963-05-07 G. Farnham Merle Treatment for "scours" in mammals
US3256150A (en) * 1964-04-20 1966-06-14 Dairyland Food Lab Method for treating malabsorption syndrome
US3991180A (en) * 1972-03-06 1976-11-09 Rohm And Haas Company Stabilization of internally administered pancreatic lipase
JPS5017559B2 (es) * 1972-09-20 1975-06-21
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
DE2638089C2 (de) * 1976-08-24 1985-04-25 Degussa Ag, 6000 Frankfurt Lipase-Präparate mit verbesserter Wirkung
GB1571877A (en) * 1978-04-24 1980-07-23 Meito Sangyo Kk Microbial lipase and its preparation
JPS6047858B2 (ja) * 1978-09-20 1985-10-24 田村 輝 温浴用水製造装置
DE2923279C2 (de) * 1979-06-08 1987-07-09 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von Pankreatin-Pellets und diese enthaltende Arzneimittel
ATE76561T1 (de) * 1985-01-09 1992-06-15 Genencor Inc Ueberfuehrung von exogenen stoffen in kaesebruch.
US4944944A (en) * 1987-11-19 1990-07-31 Oklahoma Medical Research Foundation Dietary compositions and methods using bile salt-activated lipase

Also Published As

Publication number Publication date
JP2592939B2 (ja) 1997-03-19
JPH01231848A (ja) 1989-09-18
US4944944A (en) 1990-07-31
ATE167982T1 (de) 1998-07-15
HK1023031A1 (en) 2000-08-25
HK1012213A1 (en) 1999-07-30
DE3856435D1 (de) 2000-11-30
EP0317355B1 (en) 1998-07-08
DE3856214T2 (de) 1998-12-17
EP0605913B1 (en) 2000-10-25
EP0317355A3 (en) 1991-07-17
GR3035093T3 (en) 2001-03-30
EP0605913A1 (en) 1994-07-13
ES2120402T3 (es) 1998-11-01
DE3856435T2 (de) 2001-03-29
EP0317355A2 (en) 1989-05-24
ATE197127T1 (de) 2000-11-15
JPH06315347A (ja) 1994-11-15
DE3856214D1 (de) 1998-08-13

Similar Documents

Publication Publication Date Title
ES2152941T3 (es) Utilizacion de lipasa activada de sal biliar como suplemento dietetico.
US5116624A (en) Efa compositions and therapy
MX9301835A (es) Composiciones alimenticias de derivado de vitamina d y metodo de uso.
DE3570362D1 (en) Pharmaceutical or dietetic composition having a high antithrombotic and antiarteriosclerotic activity
ES2053990T3 (es) Composiciones de acidos grasos esenciales.
BR9105986A (pt) Formulacao de liberacao por tempo de vitaminas,minerais e outros suplementos beneficos
MX168000B (es) Complemento dietetico que contiene beta-glucan complemento
ES2040232T3 (es) Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina.
EP0343694A3 (en) Agent for the treatmment and protection of the skin
AU4185696A (en) Increasing creatine and glycogen concentration in muscle
KR930000114A (ko) 지방산을 이용한 치료
EP0308197A3 (en) Method for stimulating the immune system
Ginter et al. Tissue levels and optimum dosage of vitamin C in guinea pigs
CA1275249C (en) Composition containing essential fatty acids
MY131357A (en) Fatty acid treatment
IKEGAMI et al. Effect of indigestible polysaccharides on pancreatic exocrine secretion and biliary output
JPS57126420A (en) Drug for digestive organ
KR880010762A (ko) 소화성궤양의 치료방법 및 치료용 합성물(Composition and Method for Treatment of peptic Ulcers)
KR970706271A (ko) 시냅스 전달 향상용 약제(drugs to improve synaptic transmission)
FR2534809B1 (fr) Association medicamenteuse, renfermant a titre de principes actifs, un analgesique central et la vitamine b 12 ou un derive de celle-ci
SAKURAI et al. Transport and metabolism of pyridoxine in the intestine of the mouse
HAYASHI et al. Fundamental studies on physiological and pharmacological actions of L-ascorbate 2-sulfate. VI. Effects of L-ascorbate 2-sulfate on lipid metabolism in guinea pigs
Iida Experimental studies on the craving for alcohol: II. Alcoholic drive in mice following administration of hepatotoxic agents
EP0187653A3 (en) Pharmaceutical compositions replacing the bile and aidinpharmaceutical compositions replacing the bile and aiding the digestion of fats, and process for their preparatig the digestion of fats, and process for their preparation on
WELSH et al. An appraisal of the therapeutic effect of riboflavin in psoriasis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 605913

Country of ref document: ES